Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib and Paclitaxel in Platinum-resistant Ovarian Cancer at Risk of Bowel Obstruction
NCT07648745Phase 2Completed
- Start
- May 2018
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC). Started May 2018; status: completed.
02
Drugs
cediranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07648745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07648745.